GT802 injection for relapsing or refractory multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an injection called GT802 for people with relapsing or refractory multiple sclerosis (MS) that hasn't responded to other treatments. The goal is to see if the injection is safe and can help control MS symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a confirmed diagnosis of relapsing or refractory multiple sclerosis, meaning your MS is not responding well to standard treatments.
- You have stopped other MS treatments for at least 4 weeks before starting this trial (or 5 half-lives, whichever is shorter).
- You agree to use effective birth control for at least 1 year after the infusion, and if you are breastfeeding, you agree to stop.
- You do not have severe heart, lung, or other serious health problems, and you have not had cancer in the last 5 years (except some early-stage skin or cervical cancers).
- You are not currently taking blood thinners or have bleeding problems, and you do not have active infections like HIV, hepatitis B/C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called STAR-T, which uses your own immune cells to target and attack the faulty immune cells that cause multiple sclerosis (MS). It aims to slow or stop the disease in people who have not responded to other treatments.
This trial tests a new antibody drug (GT719) for adults with autoimmune neurological diseases that came back or did not get better with standard treatment. It looks at how safe the drug is and how well it works.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
This study tests a new medicine given as a shot under the skin for people with relapsing multiple sclerosis. It aims to see if the medicine is safe and how well it works in reducing MS activity.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Hear when a new Multiple Sclerosis (MS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.